Published in Circulation on March 21, 2013
Comparable calcium handling of human iPSC-derived cardiomyocytes generated by multiple laboratories. J Mol Cell Cardiol (2015) 2.20
Patient-specific stem cells and cardiovascular drug discovery. JAMA (2013) 2.06
Screening for acute IKr block is insufficient to detect torsades de pointes liability: role of late sodium current. Circulation (2014) 1.86
Screening drug-induced arrhythmia [corrected] using human induced pluripotent stem cell-derived cardiomyocytes and low-impedance microelectrode arrays. Circulation (2013) 1.54
Deranged sodium to sudden death. J Physiol (2015) 1.51
High-throughput screening of tyrosine kinase inhibitor cardiotoxicity with human induced pluripotent stem cells. Sci Transl Med (2017) 1.44
iPS cell-derived cardiogenicity is hindered by sustained integration of reprogramming transgenes. Circ Cardiovasc Genet (2014) 1.40
Patient-specific hepatocyte-like cells derived from induced pluripotent stem cells model pazopanib-mediated hepatotoxicity. Sci Rep (2017) 1.38
Human stem cells for modeling heart disease and for drug discovery. Sci Transl Med (2014) 1.24
Isogenic human pluripotent stem cell pairs reveal the role of a KCNH2 mutation in long-QT syndrome. EMBO J (2013) 1.24
What is the point of large-scale collections of human induced pluripotent stem cells? Nat Biotechnol (2013) 1.20
Current status of pluripotent stem cells: moving the first therapies to the clinic. Nat Rev Drug Discov (2015) 1.18
Induced pluripotent stem cells: at the heart of cardiovascular precision medicine. Nat Rev Cardiol (2016) 1.13
Genome editing of isogenic human induced pluripotent stem cells recapitulates long QT phenotype for drug testing. J Am Coll Cardiol (2014) 1.08
Assessment of beating parameters in human induced pluripotent stem cells enables quantitative in vitro screening for cardiotoxicity. Toxicol Appl Pharmacol (2013) 1.08
Human iPSC-based cardiac microphysiological system for drug screening applications. Sci Rep (2015) 1.04
Epigenetic Regulation of Phosphodiesterases 2A and 3A Underlies Compromised β-Adrenergic Signaling in an iPSC Model of Dilated Cardiomyopathy. Cell Stem Cell (2015) 1.03
Human induced pluripotent stem cell-derived cardiomyocytes: insights into molecular, cellular, and functional phenotypes. Circ Res (2015) 1.02
Evolution of strategies to improve preclinical cardiac safety testing. Nat Rev Drug Discov (2016) 1.01
Finding the rhythm of sudden cardiac death: new opportunities using induced pluripotent stem cell-derived cardiomyocytes. Circ Res (2015) 0.96
Cancer treatment-related cardiotoxicity: current state of knowledge and future research priorities. J Natl Cancer Inst (2014) 0.94
Small molecule screening in human induced pluripotent stem cell-derived terminal cell types. J Biol Chem (2013) 0.93
Engineered heart tissues and induced pluripotent stem cells: Macro- and microstructures for disease modeling, drug screening, and translational studies. Adv Drug Deliv Rev (2015) 0.91
A non-invasive platform for functional characterization of stem-cell-derived cardiomyocytes with applications in cardiotoxicity testing. Stem Cell Reports (2015) 0.90
Multipotent (adult) and pluripotent stem cells for heart regeneration: what are the pros and cons? Stem Cell Res Ther (2013) 0.90
Serum supplemented culture medium masks hypertrophic phenotypes in human pluripotent stem cell derived cardiomyocytes. J Cell Mol Med (2014) 0.90
hERG 1b is critical for human cardiac repolarization. Proc Natl Acad Sci U S A (2014) 0.90
A study of early afterdepolarizations in a model for human ventricular tissue. PLoS One (2014) 0.89
Microfluidic Single-Cell Analysis of Transplanted Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes After Acute Myocardial Infarction. Circulation (2015) 0.89
Functional and pharmacological analysis of cardiomyocytes differentiated from human peripheral blood mononuclear-derived pluripotent stem cells. Stem Cell Reports (2014) 0.88
Biomaterial based cardiac tissue engineering and its applications. Biomed Mater (2015) 0.88
Concise review: drug discovery in the age of the induced pluripotent stem cell. Stem Cells Transl Med (2014) 0.86
New mechanistic and therapeutic targets for pediatric heart failure: report from a National Heart, Lung, and Blood Institute working group. Circulation (2014) 0.86
Rigorous Phenotyping of Cardiac iPSC Preparations Requires Knowledge of Their Resting Potential(s). Biophys J (2016) 0.85
Translation of Human-Induced Pluripotent Stem Cells: From Clinical Trial in a Dish to Precision Medicine. J Am Coll Cardiol (2016) 0.85
Reprogramming and transdifferentiation for cardiovascular development and regenerative medicine: where do we stand? EMBO Mol Med (2015) 0.85
Improved approach for chondrogenic differentiation of human induced pluripotent stem cells. Stem Cell Rev (2015) 0.84
Monitoring Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes with Genetically Encoded Calcium and Voltage Fluorescent Reporters. Stem Cell Reports (2015) 0.84
National Institutes of Health Center for Regenerative Medicine: putting science into practice. Stem Cells Dev (2013) 0.84
Integrated Analysis of Contractile Kinetics, Force Generation, and Electrical Activity in Single Human Stem Cell-Derived Cardiomyocytes. Stem Cell Reports (2015) 0.84
Human pluripotent stem cells: Prospects and challenges as a source of cardiomyocytes for in vitro modeling and cell-based cardiac repair. Adv Drug Deliv Rev (2015) 0.83
Screening out irrelevant cell-based models of disease. Nat Rev Drug Discov (2016) 0.83
Stem cell-derived cardiomyocytes as a tool for studying proarrhythmia: a better canary in the coal mine? Circulation (2013) 0.83
Interleukin-18 deteriorates Fabry cardiomyopathy and contributes to the development of left ventricular hypertrophy in Fabry patients with GLA IVS4+919 G>A mutation. Oncotarget (2016) 0.82
Predicting drug-induced QT prolongation and torsades de pointes. J Physiol (2016) 0.82
Cardiomyopathy in a dish: using human inducible pluripotent stem cells to model inherited cardiomyopathies. J Card Fail (2015) 0.82
Modeling susceptibility to drug-induced long QT with a panel of subject-specific induced pluripotent stem cells. Elife (2017) 0.81
Human-induced pluripotent stem cell models of inherited cardiomyopathies. Curr Opin Cardiol (2014) 0.81
A near-infrared fluorescent voltage-sensitive dye allows for moderate-throughput electrophysiological analyses of human induced pluripotent stem cell-derived cardiomyocytes. Am J Physiol Heart Circ Physiol (2014) 0.81
Patient-Specific and Genome-Edited Induced Pluripotent Stem Cell-Derived Cardiomyocytes Elucidate Single-Cell Phenotype of Brugada Syndrome. J Am Coll Cardiol (2016) 0.81
Nanopatterned Human iPSC-based Model of a Dystrophin-Null Cardiomyopathic Phenotype. Cell Mol Bioeng (2015) 0.80
Efficient differentiation of cardiomyocytes from human pluripotent stem cells with growth factors. Methods Mol Biol (2015) 0.80
Cardiovascular Disease Modeling Using Patient-Specific Induced Pluripotent Stem Cells. Int J Mol Sci (2015) 0.80
Developmental changes in electrophysiological characteristics of human-induced pluripotent stem cell-derived cardiomyocytes. Heart Rhythm (2016) 0.80
High throughput physiological screening of iPSC-derived cardiomyocytes for drug development. Biochim Biophys Acta (2016) 0.80
Human iPSC-derived cardiomyocytes and tissue engineering strategies for disease modeling and drug screening. Biotechnol Adv (2016) 0.79
hiPSC Modeling of Inherited Cardiomyopathies. Curr Treat Options Cardiovasc Med (2014) 0.79
Modeling Doxorubicin-Induced Cardiotoxicity in Human Pluripotent Stem Cell Derived-Cardiomyocytes. Sci Rep (2016) 0.79
Evaluation of the cardiotoxicity of mitragynine and its analogues using human induced pluripotent stem cell-derived cardiomyocytes. PLoS One (2014) 0.79
Identification of novel biomarkers for doxorubicin-induced toxicity in human cardiomyocytes derived from pluripotent stem cells. Toxicology (2014) 0.79
Tissue engineering the cardiac microenvironment: Multicellular microphysiological systems for drug screening. Adv Drug Deliv Rev (2015) 0.79
Using systems approaches to address challenges for clinical implementation of pharmacogenomics. Wiley Interdiscip Rev Syst Biol Med (2013) 0.79
Concise Review: Measuring Physiological Responses of Human Pluripotent Stem Cell Derived Cardiomyocytes to Drugs and Disease. Stem Cells (2016) 0.79
The Fallacy of Assigning Chamber Specificity to iPSC Cardiac Myocytes from Action Potential Morphology. Biophys J (2016) 0.79
The role of tissue engineering and biomaterials in cardiac regenerative medicine. Can J Cardiol (2014) 0.78
Liensinine- and Neferine-Induced Cardiotoxicity in Primary Neonatal Rat Cardiomyocytes and Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes. Int J Mol Sci (2016) 0.78
Inherited heart disease - what can we expect from the second decade of human iPS cell research? FEBS Lett (2016) 0.77
Induced pluripotent stem cells for cardiovascular disease: from product-focused disease modeling to process-focused disease discovery. Regen Med (2015) 0.77
Concise review: reprogramming strategies for cardiovascular regenerative medicine: from induced pluripotent stem cells to direct reprogramming. Stem Cells Transl Med (2014) 0.77
Heart failure in congenital heart disease: a confluence of acquired and congenital. Heart Fail Clin (2014) 0.77
iPSC technology--Powerful hand for disease modeling and therapeutic screen. BMB Rep (2015) 0.76
Pluripotent stem cells as a platform for cardiac arrhythmia drug screening. Curr Treat Options Cardiovasc Med (2014) 0.76
Tissue-Engineering for the Study of Cardiac Biomechanics. J Biomech Eng (2016) 0.76
Non-genetic Purification of Ventricular Cardiomyocytes from Differentiating Embryonic Stem Cells through Molecular Beacons Targeting IRX-4. Stem Cell Reports (2015) 0.76
Translational Prospects and Challenges in Human Induced Pluripotent Stem Cell Research in Drug Discovery. Cells (2016) 0.76
In vitro organogenesis from pluripotent stem cells. Organogenesis (2014) 0.76
Mutation-Specific Phenotypes in hiPSC-Derived Cardiomyocytes Carrying Either Myosin-Binding Protein C Or α-Tropomyosin Mutation for Hypertrophic Cardiomyopathy. Stem Cells Int (2015) 0.76
Human iPSC-derived cardiomyocytes cultured in 3D engineered heart tissue show physiological upstroke velocity and sodium current density. Sci Rep (2017) 0.76
Human heart disease: lessons from human pluripotent stem cell-derived cardiomyocytes. Cell Mol Life Sci (2017) 0.75
Direct hydrogel encapsulation of pluripotent stem cells enables ontomimetic differentiation and growth of engineered human heart tissues. Biomaterials (2015) 0.75
Pharmacogenetics of Potassium Channel Blockers. Card Electrophysiol Clin (2016) 0.75
Pharmacological Modulation of Calcium Homeostasis in Familial Dilated Cardiomyopathy: An In Vitro Analysis From an RBM20 Patient-Derived iPSC Model. Clin Transl Sci (2016) 0.75
Biology of the cardiac myocyte in heart disease. Mol Biol Cell (2016) 0.75
Machine learning plus optical flow: a simple and sensitive method to detect cardioactive drugs. Sci Rep (2015) 0.75
Recreating the Cardiac Microenvironment in Pluripotent Stem Cell Models of Human Physiology and Disease. Trends Cell Biol (2016) 0.75
Salvianolic Acid A, as a Novel ETA Receptor Antagonist, Shows Inhibitory Effects on Tumor in Vitro. Int J Mol Sci (2016) 0.75
Subtype-specific promoter-driven action potential imaging for precise disease modelling and drug testing in hiPSC-derived cardiomyocytes. Eur Heart J (2017) 0.75
Dominant negative consequences of a hERG 1b-specific mutation associated with intrauterine fetal death. Prog Biophys Mol Biol (2016) 0.75
Action Potential Shape Is a Crucial Measure of Cell Type of Stem Cell-Derived Cardiocytes. Biophys J (2016) 0.75
A Systemized Approach to Investigate Ca(2+) Synchronization in Clusters of Human Induced Pluripotent Stem-Cell Derived Cardiomyocytes. Front Cell Dev Biol (2016) 0.75
Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes Afford New Opportunities in Inherited Cardiovascular Disease Modeling. Cardiol Res Pract (2016) 0.75
Key Challenges and Opportunities Associated with the Use of In Vitro Models to Detect Human DILI: Integrated Risk Assessment and Mitigation Plans. Biomed Res Int (2016) 0.75
Extracellular Recordings of Patterned Human Pluripotent Stem Cell-Derived Cardiomyocytes on Aligned Fibers. Stem Cells Int (2016) 0.75
Solving the puzzle of pluripotent stem cell-derived cardiomyocyte maturation: piece by piece. Ann Transl Med (2017) 0.75
Skeletal Muscle Differentiation on a Chip Shows Human Donor Mesoangioblasts' Efficiency in Restoring Dystrophin in a Duchenne Muscular Dystrophy Model. Stem Cells Transl Med (2016) 0.75
Recapitulation of Clinical Individual Susceptibility to Drug-Induced QT Prolongation in Healthy Subjects Using iPSC-Derived Cardiomyocytes. Stem Cell Reports (2017) 0.75
L-Type Calcium Channel Inhibition Contributes to the Proarrhythmic Effects of Aconitine in Human Cardiomyocytes. PLoS One (2017) 0.75
Urine-derived induced pluripotent stem cells as a modeling tool to study rare human diseases. Intractable Rare Dis Res (2016) 0.75
Inspiration from heart development: Biomimetic development of functional human cardiac organoids. Biomaterials (2017) 0.75
21st Century Cardio-Oncology: Identifying Cardiac Safety Signals in the Era of Personalized Medicine. JACC Basic Transl Sci (2016) 0.75
Adverse drug events in hospitalized patients. Excess length of stay, extra costs, and attributable mortality. JAMA (1997) 13.66
Human cardiovascular progenitor cells develop from a KDR+ embryonic-stem-cell-derived population. Nature (2008) 10.27
Patient-specific induced pluripotent stem-cell models for long-QT syndrome. N Engl J Med (2010) 9.19
Modelling the long QT syndrome with induced pluripotent stem cells. Nature (2011) 5.68
Molecular and cellular mechanisms of cardiac arrhythmias. Cell (2001) 5.41
Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc Res (2003) 5.39
A nonviral minicircle vector for deriving human iPS cells. Nat Methods (2010) 4.42
Patient-specific induced pluripotent stem-cell-derived models of LEOPARD syndrome. Nature (2010) 4.38
Using induced pluripotent stem cells to investigate cardiac phenotypes in Timothy syndrome. Nature (2011) 4.10
Contraindicated use of cisapride: impact of food and drug administration regulatory action. JAMA (2000) 3.81
Patient-specific induced pluripotent stem cells as a model for familial dilated cardiomyopathy. Sci Transl Med (2012) 3.53
The impact of drug-induced QT interval prolongation on drug discovery and development. Nat Rev Drug Discov (2003) 3.19
Cardiomyocyte differentiation of human induced pluripotent stem cells. Circulation (2009) 2.86
Abnormal calcium handling properties underlie familial hypertrophic cardiomyopathy pathology in patient-specific induced pluripotent stem cells. Cell Stem Cell (2013) 2.33
The L-type calcium channel inhibitor diltiazem prevents cardiomyopathy in a mouse model. J Clin Invest (2002) 2.26
Anti-HERG activity and the risk of drug-induced arrhythmias and sudden death. Eur Heart J (2005) 2.24
Drug evaluation in cardiomyocytes derived from human induced pluripotent stem cells carrying a long QT syndrome type 2 mutation. Eur Heart J (2011) 2.18
Modeling of catecholaminergic polymorphic ventricular tachycardia with patient-specific human-induced pluripotent stem cells. J Am Coll Cardiol (2012) 2.13
Prediction of drug-induced cardiotoxicity using human embryonic stem cell-derived cardiomyocytes. Stem Cell Res (2009) 2.13
Drug-induced long QT and torsade de pointes: recent advances. Curr Opin Cardiol (2007) 2.04
Population-based studies of adverse drug effects. N Engl J Med (2003) 1.99
Dantrolene rescues arrhythmogenic RYR2 defect in a patient-specific stem cell model of catecholaminergic polymorphic ventricular tachycardia. EMBO Mol Med (2012) 1.93
In vitro electrophysiological drug testing using human embryonic stem cell derived cardiomyocytes. Stem Cells Dev (2010) 1.65
Progressive maturation in contracting cardiomyocytes derived from human embryonic stem cells: Qualitative effects on electrophysiological responses to drugs. Stem Cell Res (2010) 1.58
Drug-induced QT interval shortening: potential harbinger of proarrhythmia and regulatory perspectives. Br J Pharmacol (2009) 1.57
Are hERG channel inhibition and QT interval prolongation all there is in drug-induced torsadogenesis? A review of emerging trends. J Pharmacol Toxicol Methods (2005) 1.54
Quantified proarrhythmic potential of selected human embryonic stem cell-derived cardiomyocytes. Stem Cell Res (2010) 1.51
The effects of cardioactive drugs on cardiomyocytes derived from human induced pluripotent stem cells. Biochem Biophys Res Commun (2009) 1.45
The action potential and comparative pharmacology of stem cell-derived human cardiomyocytes. J Pharmacol Toxicol Methods (2010) 1.44
Effects of a K(+) channel opener to reduce transmural dispersion of repolarization and prevent torsade de pointes in LQT1, LQT2, and LQT3 models of the long-QT syndrome. Circulation (2000) 1.43
The molecular basis of chloroquine block of the inward rectifier Kir2.1 channel. Proc Natl Acad Sci U S A (2008) 1.30
Mechanisms and management of proarrhythmia. Am J Cardiol (1998) 1.30
Molecular basis of species-specific expression of repolarizing K+ currents in the heart. Am J Physiol Heart Circ Physiol (2003) 1.27
Predicting drug-induced changes in QT interval and arrhythmias: QT-shortening drugs point to gaps in the ICHS7B Guidelines. Br J Pharmacol (2008) 1.26
Pharmacogenetics and drug-induced arrhythmias. Cardiovasc Res (2001) 1.20
Pluripotent stem cell models of cardiac disease and their implication for drug discovery and development. Trends Mol Med (2011) 1.18
Alfuzosin delays cardiac repolarization by a novel mechanism. J Pharmacol Exp Ther (2007) 1.14
Embryonic stem cells in drug discovery. Nat Rev Drug Discov (2004) 1.12
Sudden death in noncoronary heart disease is associated with delayed paced ventricular activation. Circulation (2003) 1.09
Strategies to reduce late-stage drug attrition due to mitochondrial toxicity. Expert Rev Mol Diagn (2007) 1.02
Non-cardiovascular drugs that inhibit hERG-encoded potassium channels and risk of sudden cardiac death. Heart (2010) 1.01
Electrophysiological characterization of cardiomyocytes derived from human induced pluripotent stem cells. J Pharmacol Sci (2011) 0.91
Potassium channel openers are likely to be proarrhythmic in the diseased human heart. Cardiovasc Res (1994) 0.89
International Conference on Harmonisation; guidance on S7A safety pharmacology studies for human pharmaceuticals; availability. Notice. Fed Regist (2001) 0.85
Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. Nat Genet (2010) 23.08
Hundreds of variants clustered in genomic loci and biological pathways affect human height. Nature (2010) 20.01
Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Nat Genet (2011) 13.25
Clinical assessment incorporating a personal genome. Lancet (2010) 10.18
Haematopoietic stem cells adopt mature haematopoietic fates in ischaemic myocardium. Nature (2004) 8.36
Meta-analysis identifies 13 new loci associated with waist-hip ratio and reveals sexual dimorphism in the genetic basis of fat distribution. Nat Genet (2010) 7.94
Large-scale association analysis identifies new risk loci for coronary artery disease. Nat Genet (2012) 7.59
Ca2+/calmodulin-dependent protein kinase modulates cardiac ryanodine receptor phosphorylation and sarcoplasmic reticulum Ca2+ leak in heart failure. Circ Res (2005) 5.34
In vivo visualization of embryonic stem cell survival, proliferation, and migration after cardiac delivery. Circulation (2006) 4.48
A nonviral minicircle vector for deriving human iPS cells. Nat Methods (2010) 4.42
Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation. Ann Intern Med (2010) 4.16
The deltaC isoform of CaMKII is activated in cardiac hypertrophy and induces dilated cardiomyopathy and heart failure. Circ Res (2003) 4.13
Local InsP3-dependent perinuclear Ca2+ signaling in cardiac myocyte excitation-transcription coupling. J Clin Invest (2006) 3.72
A mathematical treatment of integrated Ca dynamics within the ventricular myocyte. Biophys J (2004) 3.72
Production of de novo cardiomyocytes: human pluripotent stem cell differentiation and direct reprogramming. Cell Stem Cell (2012) 3.66
Feeder-free derivation of induced pluripotent stem cells from adult human adipose stem cells. Proc Natl Acad Sci U S A (2009) 3.57
Patient-specific induced pluripotent stem cells as a model for familial dilated cardiomyopathy. Sci Transl Med (2012) 3.53
Ca2+ scraps: local depletions of free [Ca2+] in cardiac sarcoplasmic reticulum during contractions leave substantial Ca2+ reserve. Circ Res (2003) 3.47
Beta-adrenergic enhancement of sarcoplasmic reticulum calcium leak in cardiac myocytes is mediated by calcium/calmodulin-dependent protein kinase. Circ Res (2007) 3.46
Human tissue-engineered blood vessels for adult arterial revascularization. Nat Med (2006) 3.39
Ca2+/calmodulin-dependent protein kinase II regulates cardiac Na+ channels. J Clin Invest (2006) 3.33
Ca2+/Calmodulin-dependent protein kinase II phosphorylation of ryanodine receptor does affect calcium sparks in mouse ventricular myocytes. Circ Res (2006) 3.26
Phased whole-genome genetic risk in a family quartet using a major allele reference sequence. PLoS Genet (2011) 3.20
An antibody against SSEA-5 glycan on human pluripotent stem cells enables removal of teratoma-forming cells. Nat Biotechnol (2011) 3.05
Elevated sarcoplasmic reticulum Ca2+ leak in intact ventricular myocytes from rabbits in heart failure. Circ Res (2003) 3.04
Transgenic CaMKIIdeltaC overexpression uniquely alters cardiac myocyte Ca2+ handling: reduced SR Ca2+ load and activated SR Ca2+ release. Circ Res (2003) 3.04
Cellular basis of triggered arrhythmias in heart failure. Trends Cardiovasc Med (2004) 2.97
Quantitative assessment of the SR Ca2+ leak-load relationship. Circ Res (2002) 2.93
Transplantation for idiopathic pulmonary arterial hypertension: improvement in the lung allocation score era. Circulation (2013) 2.87
Cellular basis of abnormal calcium transients of failing human ventricular myocytes. Circ Res (2003) 2.86
Persistent donor cell gene expression among human induced pluripotent stem cells contributes to differences with human embryonic stem cells. PLoS One (2010) 2.86
Transcriptional and functional profiling of human embryonic stem cell-derived cardiomyocytes. PLoS One (2008) 2.85
Hypercontractile female hearts exhibit increased S-nitrosylation of the L-type Ca2+ channel alpha1 subunit and reduced ischemia/reperfusion injury. Circ Res (2006) 2.84
SparkMaster: automated calcium spark analysis with ImageJ. Am J Physiol Cell Physiol (2007) 2.84
Susceptibility locus for clinical and subclinical coronary artery disease at chromosome 9p21 in the multi-ethnic ADVANCE study. Hum Mol Genet (2008) 2.71
Single cell transcriptional profiling reveals heterogeneity of human induced pluripotent stem cells. J Clin Invest (2011) 2.69
Adverse cardiovascular events temporally associated with ma huang, an herbal source of ephedrine. Mayo Clin Proc (2002) 2.67
CaMKII in myocardial hypertrophy and heart failure. J Mol Cell Cardiol (2011) 2.65
Imaging survival and function of transplanted cardiac resident stem cells. J Am Coll Cardiol (2009) 2.58
Increased sarcoplasmic reticulum calcium leak but unaltered contractility by acute CaMKII overexpression in isolated rabbit cardiac myocytes. Circ Res (2005) 2.50
MicroRNA profiling of human-induced pluripotent stem cells. Stem Cells Dev (2009) 2.44
Detailed physiologic characterization reveals diverse mechanisms for novel genetic Loci regulating glucose and insulin metabolism in humans. Diabetes (2010) 2.44
A novel computational model of the human ventricular action potential and Ca transient. J Mol Cell Cardiol (2009) 2.36
Short-term immunosuppression promotes engraftment of embryonic and induced pluripotent stem cells. Cell Stem Cell (2011) 2.35
Abnormal calcium handling properties underlie familial hypertrophic cardiomyopathy pathology in patient-specific induced pluripotent stem cells. Cell Stem Cell (2013) 2.33
Intracellular Na(+) concentration is elevated in heart failure but Na/K pump function is unchanged. Circulation (2002) 2.32
MicroRNA-210 as a novel therapy for treatment of ischemic heart disease. Circulation (2010) 2.32
Ryanodine receptor phosphorylation by calcium/calmodulin-dependent protein kinase II promotes life-threatening ventricular arrhythmias in mice with heart failure. Circulation (2010) 2.32
Effects of cell number on teratoma formation by human embryonic stem cells. Cell Cycle (2009) 2.30
Role of Ca2+/calmodulin-dependent protein kinase (CaMK) in excitation-contraction coupling in the heart. Cardiovasc Res (2006) 2.30
Kinetics of FKBP12.6 binding to ryanodine receptors in permeabilized cardiac myocytes and effects on Ca sparks. Circ Res (2010) 2.29
Approximate model of cooperative activation and crossbridge cycling in cardiac muscle using ordinary differential equations. Biophys J (2008) 2.29
Sarcoplasmic reticulum Ca2+ and heart failure: roles of diastolic leak and Ca2+ transport. Circ Res (2003) 2.28
Sarcoplasmic reticulum and nuclear envelope are one highly interconnected Ca2+ store throughout cardiac myocyte. Circ Res (2006) 2.27
Cardiac alternans do not rely on diastolic sarcoplasmic reticulum calcium content fluctuations. Circ Res (2006) 2.25
Immunosuppressive therapy mitigates immunological rejection of human embryonic stem cell xenografts. Proc Natl Acad Sci U S A (2008) 2.25
Dynamic microRNA expression programs during cardiac differentiation of human embryonic stem cells: role for miR-499. Circ Cardiovasc Genet (2010) 2.24
Comparison of different adult stem cell types for treatment of myocardial ischemia. Circulation (2008) 2.22
Na(+)-Ca(2+) exchange current and submembrane [Ca(2+)] during the cardiac action potential. Circ Res (2002) 2.21
Differentiation, survival, and function of embryonic stem cell derived endothelial cells for ischemic heart disease. Circulation (2007) 2.21
Human cardiac progenitor cells engineered with Pim-I kinase enhance myocardial repair. J Am Coll Cardiol (2012) 2.18
Lack of association between the Trp719Arg polymorphism in kinesin-like protein-6 and coronary artery disease in 19 case-control studies. J Am Coll Cardiol (2010) 2.17
Consensus conference report: maximizing use of organs recovered from the cadaver donor: cardiac recommendations, March 28-29, 2001, Crystal City, Va. Circulation (2002) 2.14
Termination of cardiac Ca2+ sparks: role of intra-SR [Ca2+], release flux, and intra-SR Ca2+ diffusion. Circ Res (2008) 2.12
Phospholamban ablation rescues sarcoplasmic reticulum Ca(2+) handling but exacerbates cardiac dysfunction in CaMKIIdelta(C) transgenic mice. Circ Res (2009) 2.12
Embryonic stem cell immunogenicity increases upon differentiation after transplantation into ischemic myocardium. Circulation (2005) 2.12
A bivariate genome-wide approach to metabolic syndrome: STAMPEED consortium. Diabetes (2011) 2.09
Diabetic hyperglycaemia activates CaMKII and arrhythmias by O-linked glycosylation. Nature (2013) 2.08
Protein kinase A phosphorylation of the ryanodine receptor does not affect calcium sparks in mouse ventricular myocytes. Circ Res (2002) 2.06
Patient-specific stem cells and cardiovascular drug discovery. JAMA (2013) 2.06
Dissecting the molecular relationship among various cardiogenic progenitor cells. Circ Res (2013) 2.06
Procedural complications, rehospitalizations, and repeat procedures after catheter ablation for atrial fibrillation. J Am Coll Cardiol (2012) 2.05
Effects of intracoronary CD34+ stem cell transplantation in nonischemic dilated cardiomyopathy patients: 5-year follow-up. Circ Res (2012) 2.02
Characterizing the admixed African ancestry of African Americans. Genome Biol (2009) 2.01
Ca²+ spark-dependent and -independent sarcoplasmic reticulum Ca²+ leak in normal and failing rabbit ventricular myocytes. J Physiol (2010) 2.01